Generation Bio Co. secured $110 million in series C funding led by T. Rowe Price Group Inc. funds and accounts.

Farallon Capital Management LLC and Wellington Management Co. LLP also participated in the round, alongside existing backers Atlas Venture LP, Fidelity Management & Research Co., The Invus Group LLC, Casdin Capital LLC, Deerfield Management Co. LP, Foresite Capital Management LLC and an entity related to SVB Leerink LLC.

The gene therapy-focused biotechnology company will use the new capital to move its two liver-targeted programs for hemophilia A and phenylketonuria into investigational new drug-enabling studies and clinical development.

Cowen was the exclusive placement agent for the funding round.